International health report reinforces huge threat from major killer condition - thrombosis

  

 

A milestone report has spotlighted a condition escaping close attention yet killing more people in the US and Europe annually than AIDS, breast cancer, prostate cancer, and road accidents combined.

The collective term for various forms of thrombosis is Venous Thromboembolism (VTE) and includes Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).

All are now likely to be watched more closely following Venous Thromboembolism Market Insights, Epidemiology, and Market Forecast-2032, a report from business consulting and market research company DelveInsight, highlighting the condition’s consequences, new drug developments and companies targeting it.

Caption: International health report reinforces huge threat from major killer condition - thrombosis

 

Thrombosis occurs when blood clots block veins or arteries, with symptoms including pain and swelling in one leg, chest pain, or numbness to one side of the body. Complications can lead to a stroke, heart attack and death.

The thrombosis market has quietly gathered momentum behind COVID-19’s domination of headlines, as shown by a 2021 Data Bridge Market Research forecast that thrombosis treatments would be worth almost $17 billion globally by 2028, growing at a CAGR of 8.59%.

The DelveInsight report named a pioneering drug company in its findings, Silicon Valley-based Verseon, which is using its proprietary AI and advanced computational drug discovery platform to develop cardiovascular treatments alongside seven other drug candidates it aims to bring to market soon, including an oral drug targeting all COVID-19 variants and other coronaviruses at source.

Adityo Prakesh, CEO at Verseon, in Fremont, California said thrombosis in all its forms had been hiding in plain sight for decades:

“Thrombosis poses a serious risk of stroke and heart attack to over 400 million people with cardiovascular disease worldwide. But finding anti-thrombotic drugs with a very low bleeding risk and safe for long-term use remains a challenge for the rest of the industry.

“However, our PROAC (precision oral anticoagulant) candidates promise to provide a safe long-term therapy option for cardiovascular patients, and we are excited that DelveInsight has raised awareness of our programs in its report.”

Verseon’s Chief Science Officer David Kita added: “Our PROACs work by a different mechanism of action from any other marketed anticoagulant.

“They prevent undesired blood clot formation, yet also preserve hemostasis (blood flow) and promise a dramatically reduced bleeding risk. They have the potential to change the standard of care for millions of patients with thrombosis-related disorders.”

Verseon’s claims have been endorsed by a globally renowned expert, John Deanfield, Professor of Cardiology at University College London – who famously coined the health concept 'invest in your arteries'.

“Verseon’s platelet-sparing anticoagulants…represent an exciting ‘precision medicine’ opportunity for the treatment of a large population of cardiovascular disease patients,” said Prof Deanfield.

The campaign World Thrombosis Day, founded in 2014, highlights VTE on the same day every year – October 13 – and quotes chilling annual figures: some 10 million cases of VTE worldwide; 100-300,000 Americans and around 550,000 Europeans dying from VTE-related conditions; and VTE-related events claiming more lives than AIDS, breast cancer, prostate cancer and road crashes combined.

And up to 60 percent of VTE cases occur during or after hospitalization, making it a leading preventable cause of hospital death.

Delvelnsight’s Venous Thromboembolism Market Insights, Epidemiology, and Market Forecast-2032 is intended to be a game-changing insight into historical and forecast analysis of VTE’s distribution, patterns, and causes as well as market trends in the US, EU5 (Germany, Spain, Italy, France, and UK) and Japan.

It says market change and growth is inevitable due to emerging therapies from Verseon and the other companies named: Bayer and Bayer/Ionis, Bristol-Myers Squibb/Janssen, Quercis Pharma, and Ono.

International Society on Thrombosis and Haemostasis Surpasses Attendance Records for Annual Scientific and Standardization Committee Meeting in Dublin

 The International Society on Thrombosis and Haemostasis (ISTH) will hold its 64th Annual Scientific and Standardization Committee (SSC) Meeting from July 18-21, 2018, in Dublin, Ireland at the Dublin Convention Centre. The meeting has grown by more than 50 percent in attendance compared to the last ISTH SSC stand-alone meeting in 2016, welcoming more than 3,000 clinicians, researchers, educators, healthcare professionals and industry partners from across the globe.

Building on the success of previous SSC meetings, ISTH SSC 2018 will cover the fields’ most talked about topics, including atherothrombosis and stroke, coagulant and anticoagulant mechanisms, management of thromboembolisms and other areas of expertise. It is also the last SSC stand-alone meeting as the ISTH transitions to a yearly congress format in 2019 in Melbourne, Australia.

ISTH SSC 2018 is poised to provide valuable insights for a global readership by showcasing new clinical findings, diagnostic and therapeutic approaches and scientific studies and advancements through an extensive line up of educational and sponsored sessions and activities. Such activities include plenaries, education and breakout sessions led by SSC Subcommittees, and an exhibition hall featuring companies from around the world.

The meeting will also showcase innovative offerings to enhance the attendee experience, such as a state-of-the-art mobile app, exclusive networking opportunities for early career professionals, conference capture capabilities, meet-the-mentor sessions, virtual delegate bag, business meet-up zones, and more.

In addition to an increase in meeting attendance, the ISTH SSC 2018 meeting received a 58 percent rise in abstracts from 2016.

The ISTH SSC holds annual meetings devoted to the discussion of diagnostic standards, disease nomenclature and classification and the latest research on bleeding and thrombotic disorders. Explore this year’s program and discover more about the ISTH’s commitment to science and research leading to improved patient care.

International Society on Thrombosis and Haemostasis Partners with Wiley to Launch New Open Access Journal

  The International Society on Thrombosis and Haemostasis (ISTH), in partnership with John Wiley and Sons, Inc. (NYSE: JWa and JWb), announces the launch of the Society’s new open access journal, Research and Practice in Thrombosis and Haemostasis (RPTH), with its inaugural issue to publish in conjunction with the meeting of the ISTH 2017 Congress in Berlin, Germany, July 8-13.

Complementing the Society’s flagship journal, the Journal of Thrombosis and Haemostasis (JTH), RPTHwill provide an innovative new open access platform for science and discourse among researchers, clinicians and patients. It will publish a broad array of article types covering the widest possible spectrum of topics in thrombosis, hemostasis and related areas. Studies by multidisciplinary research groups, from emerging areas of research and from under-represented regions of the world, will be of particular interest.

Mary Cushman, M.D., M.Sc., professor of medicine at the Larner College of Medicine at the University of Vermont, and director of the thrombosis and hemostasis program at the University of Vermont Medical Center in the United States, will lead the launch of the journal as its inaugural Editor-in-Chief. The editorial team working with Dr. Cushman represents all areas of the world and includes: PantepAngchaisuksiri (Thailand), Cihan Ay (Austria), Suzanne Cannegieter (The Netherlands), Adam Cuker (USA), Susan Kahn (Canada), Fiona Newell (Australia), Yotis Senis (UK) and Alisa Wolberg (USA).

“RPTH epitomizes the current era of inter-disciplinary scientific discovery and new methods of knowledge dissemination,” Cushman said. “Capitalizing on its open access and online-only format,RPTH will provide unrestricted access to scientific results from around the globe as a ‘living journal,’ serving as an important catalyst for digital discussion. In so doing, it will also provide the public with ease of access to research findings.”

Published in partnership with Wiley, RPTH is interested in basic, clinical, translational and population or public health research. Studies and trials covering quality of care, outcomes, dissemination and implementation science are sought, including work on novel care delivery especially in areas of resource constraint around the world.

Boston Scientific Joins World Thrombosis Day Campaign

The International Society on Thrombosis and Haemostasis (ISTH) is pleased to announce that Boston Scientific, a company that transforms lives through innovative medical solutions that improve the health of patients around the world, has committed to serve as an official Global Partner for its World Thrombosis Day campaign.

A year-long campaign recognized on 13 October, World Thrombosis Day focuses attention on the often overlooked and misunderstood condition of thrombosis. With thousands of educational events in more than 80 countries around the world, World Thrombosis Day and its partners place a global spotlight on thrombosis as an urgent and growing health problem. Together, the collaboration aims to reduce death and disability caused by thrombosis.

“Given that worldwide, one in four people die from conditions caused by thrombosis, there is a critical need for the global effort behind the World Thrombosis Day campaign,” said Dr. Keith Dawkins, executive vice president and global chief medical officer, Boston Scientific. “On joining the campaign as a Global Partner, Boston Scientific is proud to support the World Thrombosis Day organization in driving efforts that help educate on thrombosis causes, symptoms and available treatment options that can help millions overcome this life-threatening condition.”

In its third year, the World Thrombosis Day campaign seeks to ensure citizens of the world “Know Thrombosis” and understand the steps to take to “Keep Life Flowing.” Based on a global survey conducted in nine countries among men and women, too few people know about thrombosis, specifically blood clots in the leg (deep vein thrombosis) and lungs (pulmonary embolism) and their life-threatening consequences. The campaign urges people to: 1) Know the risk factors; 2) Know the signs and symptoms; 3) Be proactive and talk to a health care professional about risk and prevention of blood clots, especially if admitted to the hospital or having surgery.

“We are honored to welcome Boston Scientific as an official Global Partner of the campaign,” said Dr. Gary Raskob, dean of the College of Public Health, University of Oklahoma Health Sciences Center, and chairman of the World Thrombosis Day Steering Committee. “We are excited to work together to increase awareness at all levels – personal, health care systems, providers, and policy makers – to collectively encourage prevention and to continue addressing thrombosis as an urgent and growing health problem.”   

World Thrombosis Day: Join the Global Movement and Help Save Lives

 Recent reports indicate that R&B artist Tamar Braxton recently exited the Dancing with the Stars competition due to a pulmonary embolism (PE), which is a blockage of arteries in the lung(s) by a blood clot. Braxton is the second Dancing with the Stars participant this season to withdraw from the competition due to illness with Kim Zolciak forced to withdraw after a mini stroke, also caused by a blood clot. With this news, as well as other notable celebrities and spokespeople such as Chris Bosh, Brian Vickers and Serena Williams experiencing blood clots -- deep vein thrombosis (DVT), pulmonary embolisms (PE) and together venous thromboembolisms (VTE) -- it’s important for the public to hear from a notable expert in the field. After all, research shows that 1 in 4 people around the world die of causes related to thrombosis. The good news is that it is preventable.

Dr. Gary E. Raskob, Dean of the Department of Public Health at the University of Oklahoma Health Sciences Center, Regents Professor of Epidemiology and Medicine and World Thrombosis Day Steering Committee Chair, is available for media interviews to discuss the causes, risk factors, signs/symptoms and evidence-based prevention and treatment of thrombosis. As a global key opinion leader in the field, Dr. Raskob’s research and scholarly interests are in the prevention, diagnosis and treatment of deep-vein thrombosis and pulmonary embolism; the clinical development of antithrombotic drugs; clinical trials; prevention research; evidence-based medicine; and the translation of research evidence into practice and health policy. Dr. Raskob is also a member of the International Society on Thrombosis and Haemostasis (ISTH).

Dr. Raskob is available if you’d like to schedule an interview. Please contact Barbara Krolak, ISTH Campaign Specialist, at Barbara_Krolak@isth.org or (919) 929-3807.

MORE INFORMATION

According to the ISTH’s World Thrombosis Day campaign, thrombosis is a serious healthcare issue that requires immediate attention and action. When a clot forms in a deep vein, usually in the leg, it is called a deep vein thrombosis or DVT; if that clot breaks loose and travels to the lungs, it is called a pulmonary embolism or PE. Together, deep vein thrombosis (DVT) and pulmonary embolism (PE) are known as venous thromboembolism (VTE). VTE is an extremely dangerous and potentially deadly medical condition. Each year, there are nearly 10 million cases of VTE worldwide—leading to 600,000 each year in Europe and the U.S. alone. Furthermore, 60 percent are hospital associated. To learn more and view infographics that can help show the mechanisms of a blood clot visit www.worldthrombosisday.org.